News
QURE
24.97
+2.84%
0.69
Weekly Report: what happened at QURE last week (1019-1023)?
Weekly Report · 2d ago
Will Disappointing Trial Data Change uniQure (QURE) Stock Narrative
Simply Wall St · 10/20 14:32
Weekly Report: what happened at QURE last week (1012-1016)?
Weekly Report · 10/19 09:52
uniQure Price Target Raised to $48.00/Share From $27.00 by UBS
Dow Jones · 10/15 21:54
uniQure Coverage Assumed by UBS at Buy
Dow Jones · 10/15 21:54
uniQure: The Market Graded The Wrong Exam
Seeking Alpha · 10/15 14:24
Cedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint
Seeking Alpha · 10/15 13:20
uniQure assumed with a Buy at UBS
TipRanks · 10/15 00:35
UBS Initiates a Buy Rating on uniQure (QURE)
TipRanks · 10/14 23:56
Weekly Report: what happened at QURE last week (1005-1009)?
Weekly Report · 10/12 09:56
Is uniQure (QURE) Undervalued On New Huntingtons Data And FDA Filing Clarity?
Simply Wall St · 10/08 04:55
Cedar Grove Capital Q3 2026 Portfolio Update
Seeking Alpha · 10/07 19:48
Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)
Simply Wall St · 10/07 02:22
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop
Barchart · 10/06 17:00
uniQure Cut to Equal-Weight From Overweight by Barclays
Dow Jones · 10/05 13:17
uniQure Price Target Cut to $28.00/Share From $60.00 by Barclays
Dow Jones · 10/05 13:17
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28
Benzinga · 10/05 13:06
uniQure downgraded to Equal Weight from Overweight at Barclays
TipRanks · 10/05 11:35
Weekly Report: what happened at QURE last week (0928-1002)?
Weekly Report · 10/05 09:55
uniQure Price Target Cut to $48.00/Share From $65.00 by RBC Capital
Dow Jones · 10/02 13:51
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.